Case report: Dendritic cell-cytokine induced killer cell therapy in subjects with chronic lymphocytic leukemia and peritoneal cancer

Frontiers in Medicine

Medicine

Doreen Santora¹  Brian Mehling¹  Ellen O’Gorman¹  Daniel Sheridan¹  Renata Mihályová²  DongCheng Wu³ 

[1] BHI Therapeutic Sciences Inc., Hackensack, NJ, United States;Blue Horizon International, Bratislava, Slovakia;Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China;

关键词: immunotherapy;    cancer;    dendritic cells;    cytokine-induced killer cells;    leukemia;    peritoneal cancer;   

DOI  :  10.3389/fmed.2023.1240330

 received in 2023-06-14, accepted in 2023-09-11,  发布年份 2023

来源: Frontiers

【 摘 要 】

This study aimed to characterize the safety and efficacy of DC-CIK therapy in two patients with previously treated chronic lymphocytic leukemia or peritoneal cancer, respectively. Participants had received conventional chemotherapy treatment for their specific cancers, and in addition, 1–2 treatments of DC-CIK therapy were administered to subjects over the course of 1 year. Subject A received an initial dosage of 3 intravenous infusions of DC-CIK therapy on three successive days and a repeat dosage 6 months later. Subject B received an initial dosage of 3 intravenous infusions of DC-CIK therapy on three successive days and received further chemotherapy after approximately 1 year. No treatment-related adverse events were reported, and both patients experienced favorable outcomes from the treatment, including enhanced treatment response, increased chemotherapy tolerance, and prolonged survival in comparison to typical 5-year survival rates.

【 授权许可】

Unknown   
Copyright © 2023 Mehling, Wu, O’Gorman, Sheridan, Santora and Mihályová.